Apellis Pharmaceuticals Inc.

APLS | NASDAQ

Price Alert Chart Builder DCF Calculator

$41.03

$0 (0.00%)

At close: May 15, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $5.25B

Enterprise Value $4.96B

Beta -0.25

Average Volume 4.87M

Shares Outstanding (Diluted) N/A

Shares Change YoY N/A

Institutional Ownership N/A

Exchange NASDAQ

ISIN US03753U1060

Price Performance

Price Change 1M 0.3%

Price Change 3M 80.0%

Price Change 6M 109.2%

Price Change YTD 58.7%

Price Change 1Y 121.7%

Price Change 3Y -52.8%

Price Change 5Y -14.2%

1M CAGR (ann.) 1.5%

1Y CAGR (ann.) 145.7%

5Y CAGR (ann.) -1.9%

All-Time CAGR 13.4%

Valuation

PE Ratio 45.09

Forward PE N/A

PEG Ratio 0.07

Forward PEG -0.42

PS Ratio 5.10

Forward PS 5.10

PB Ratio 12.66

P/FCF Ratio 139.04

P/Adj. FCF Ratio 131.38

P/OCF Ratio 136.77

EV/Sales 4.82

EV/EBIT 33.23

EV/EBITDA 28.05

EV/FCF 131.32

Earnings Yield 2.2%

FCF Yield 0.7%

Adj. FCF Yield 0.8%

Financial Health

Net Cash $291.69M

Total Debt $113.51M

Cash & Short-Term Investments $405.21M

Total Assets $1.08B

Current Ratio 3.63

Quick Ratio 3.16

Debt / Equity Ratio 1.15

Debt / EBITDA 0.64

Debt / FCF 3.00

OCF / Debt 0.33

Interest Coverage 3.79

Altman Z-Score 3.08

Piotroski F-Score 6

Margins & Profitability

Gross Profit Margin 90.1%

Operating Profit Margin 16.1%

EBITDA Margin 16.3%

Net Profit Margin 12.1%

FCF Margin 3.7%

Adj. FCF Margin 3.9%

SBC / Revenue -0.2%

SBC Impact (per share) -5.8%

Returns

Return on Assets 12.3%

Return on Equity 39.7%

Return on Invested Capital 18.1%

Return on Capital Employed 20.7%

Return on Tangible Assets 12.3%

Historical Growth (CAGR)

Revenue CAGR 3Y 113.4%

Revenue CAGR 5Y 32.6%

Revenue CAGR 10Y 38.3%

EPS CAGR 3Y 151.0%

EPS CAGR 5Y 60.2%

EPS CAGR 10Y 2.8%

FCF CAGR 3Y 169.3%

FCF CAGR 5Y 52.1%

FCF CAGR 10Y -5.8%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 25

EPS Growth Next 3Y 19.7%

Revenue Growth Next 3Y 10.0%

Earnings Date Jul 29, 2026

EPS Estimate (next Q) -$0.33

EPS Growth Est (next Q) 0.0%

Revenue Est (next Q) $208.05M

Revenue Growth Est (next Q) 16.6%

Fair Value Estimates

Graham Number $8.21

Graham Upside -80.0%

Lynch Fair Value $22.75

Lynch Upside -44.5%

Price Target $62

Price Target Upside 51.1%

Cash Flow

Operating Cash Flow $37.77M

Free Cash Flow $37.78M

Adj. Free Cash Flow $39.98M

FCF Per Share $0.30

OCF Per Share $0.30

OCF/S Ratio 3.4%

Income Statement

Revenue $1.03B

Gross Profit $920.13M

Operating Income $165.22M

EBITDA $176.85M

Net Income $133.27M

EPS (Diluted) $0.91

Revenue / Employee $1.46M

Profit / Employee $189.03K

Employees 705